Objective-To compare the efficacy and safety of cholestyramine, an anion exchange resin, and pravastatin, a new hydrophilic specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in the treatment of heterozygous familial hypercholesterolaemia.
g/day) led to similar reductions in concentrations of total cholesterol (23%) and low density lipoprotein cholesterol (31%). No consistent changes occurred in high density lipoprotein cholesterol values with either compound. Plasma triglyceride concentrations showed a small rise (18%) on resin therapy. No serious adverse drug reactions occurred during the study.
Conclusions-Pravastatin seems to be a highly effective, well tolerated drug for severe hypercholesterolaemia. Patients chosen for this study were recruited on the basis that they could tolerate a full dose of cholestyramine, and in this situation cholestyramine was also highly effective in lowering plasma low density lipoprotein cholesterol concentrations.
Introduction
Increasing evidence points to a causal role for low density lipoprotein in atherosclerosis related disease, particularly coronary heart disease.' 2 Primary prevention trials of cholesterol lowering drugs in high risk, middle aged men have provided strong evidence of benefit in terms of reduced incidence of coronary heart disease." In addition, recent coronary angiographic studies have shown that lipid lowering therapy has a significant impact on atheroma plaque development, progression, and regression."
People with familial hypercholesterolaemia have a particularly high risk of coronary heart disease. This autosomal dominant disorder is characterised clinically by hypercholesterolaemia, tendon xanthomas, and the development ofpremature coronary heart disease; over half of male heterozygotes and 15% of women die before the age of 60.9 The genetic abnormality has been well described by Brown The study was double blind, double dummy, and placebo controlled with the following three parallel groups: (1) pravastatin 20 mg twice daily and cholestyramine placebo, (2) cholestyramine 16-24 g daily in divided doses and pravastatin placebo, and (3) pravastatin placebo and cholestyramine placebo.
The primary focus of the study was comparison of the two treatment groups with the placebo group at 12 weeks. However, to obtain more long term data groups 1 and 2 were continued on treatment for 24 weeks. In addition, group 3 receiving double placebo were rerandomised to receive active treatment with pravastatin or cholestyramine with appropriate placebo for a further 12 weeks.
Cholestyramine (16-24 g) was taken well diluted with fluid before meals in two or three divided doses cholesterol concentration, and ratio of low density lipoprotein cholesterol to high density lipoprotein cholesterol in the two active treatment groups compared with the placebo group (p<0 001). Pravastatin was associated with a 25% fall in plasma cholesterol concentration at 12 weeks. A significant fall in plasma cholesterol value was seen at two weeks and was maximal at four weeks. The reduction in total plasma cholesterol concentration was explained by a reduction in low density lipoprotein cholesterol of 30%. There was no change in the concentration of high density lipoprotein cholesterol, but a highly significant reduction in the ratio of low density lipoprotein cholesterol to high density lipoprotein cholesterol was observed (p<0001). Plasma triglyceride concentration fell by 14%; this reduction was not significantly different from that in the placebo group, although it was significantly different from baseline (p<005).
Cholestyramine produced similar reductions in total plasma cholesterol concentration (23%), low density lipoprotein cholesterol concentration (31%), and ratio of low density lipoprotein cholesterol to high density lipoprotein cholesterol (34%) to those observed with pravastatin. However, plasma triglyceride concentrations rose (18%) on treatment with the resin (p<-0 1).
The results observed at 12 weeks for lipid and lipoprotein parameters were maintained at 24 weeks. In the pravastatin treated group the mean reductions in total and low density lipoprotein cholesterol concentrations were 24% and 30% respectively. Plasma triglyceride concentration was reduced by 17%. In the cholestyramine treated group the mean reductions in total and low density lipoprotein cholesterol values were 20% and 26% respectively. Plasma triglyceride concentration was increased by 6%. The placebo groups assimilated at 12 weeks were not distinguishable at 24 weeks from the active treatment groups.
WITHDRAWALS AND ADVERSE EVENTS
No serious adverse drug reactions occurred during the study. Six patients were withdrawn because of symptoms, four on cholestyramine and one on placebo because of gastrointestinal symptoms and one from the pravastatin group for a rash which resolved after the drug was stopped. These patients were withdrawn within the 12 week placebo controlled treatment period.
No patient withdrew because of ocular problems or myositis-like symptoms. Three patients (one taking cholestyramine, one pravastatin, and one placebo) withdrew within the first 12 weeks for personal reasons (two due to job commitments, one unwilling to enter long term treatment). One further patient was withdrawn from the cholestyramine group because baseline lipid values were below the inclusion eligibility level.
LABORATORY EVALUATIONS
No patient was withdrawn from the study because of changes in liver function values. Transient increases in y-glutamyltransferase activities (>1 5+ baseline) were seen in three patients taking pravastatin and five on cholestyramine. However, activities of this enzyme rose above the upper limit of the normal range in only two patients, one on cholestyramine and one on pravastatin. This abnormality was observed at two time points in the cholestyramine treated patient and one time point in the pravastatin treated patient. Nine patients receiving pravastatin showed transient disturbances of other hepatic enzyme values, which were not associated with clinical symptoms and did not lead to withdrawal of the patients. In addition, similar changes in hepatic enzyme values were observed in three patients receiving cholestyramine and one receiving placebo. There were no significant alterations in haematological parameters. No patient showed persistently raised creatine kinase activities during the studv. Transient increases (>4xbaseline) were observed in eight subjects-four on placebo, two on cholestyramine, and two on pravastatin.
Discussion
The cellular cholesterol pool regulates the expression ofcell membrane low density lipoprotein receptors which play a major part in controlling plasma low density lipoprotein cholesterol concentrations. When the cellular cholesterol pool is reduced low density lipoprotein receptor numbers increase which bind and take up low density lipoprotein cholesterol to maintain cellular cholesterol homoeostasis."' The major regulatory step in cellular cholesterol synthesis is the conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonic acid, which is catalysed by the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase. The discovery of naturally occurring inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase provided the opportunity for a physiological means of modifying cholesterol biosynthesis and the cellular cholesterol pool." '9 The introduction of these inhibitors into clinical practice represents a major advance in the pharmacological modification of low density lipoprotein cholesterol concentrations.' 2(0-22 In this study we have compared the safety and efficacy of pravastatin, a new hydrophilic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, with cholestyramine. Pravastatin increases the expression of low density lipoprotein receptors in human liver. 21 Cholestyramine is a basic anion exchange resin which remains unabsorbed after oral administration and binds to bile acids in the intestine, preventing their reabsorption. In response, more bile acid is produced in the liver from cholesterol, leading to increased expression of low density lipoprotein receptors.24 Hepatic cholesterol synthesis is also increased, which partially offsets the cholesterol lowering effect.
PATIENT SELECTION
The patients chosen for this study were heterozygous for familial hypercholesterolaemia and at high risk of premature coronary heart disease. These patients almost invariably require drug therapy in addition to nutritional counselling to reduce plasma low density lipoprotein cholesterol concentrations to near normal.2 At present there is no straightforward biochemical measure of low density lipoprotein receptor activity which will fully discriminate between heterozygotes for familial hypercholesterolaemia and normal people. Therefore, the familial hypercholesterolaemic subjects were identified on strict biochemical and clinical criteria, including the presence of tendon xanthomas to ensure as homogeneous a population as possible for study. This inevitably leads to bias in the selection of subjects, in that subjects without xanthomas (or without xanthomas in a first degree relative) were excluded. However, there is no evidence to suggest a differential response to treatment between xanthomatous and non-xanthomatous disease.
DRUG EFFECTS
In this study pravastatin and cholestyramine produced similar, substantial reductions in plasma cholesterol concentrations through the reduction of plasma low density lipoprotein cholesterol. The reduction of low density lipoprotein cholesterol of 30% with pravastatin was in line with results in a dose-response study in primary hypercholesterolaemia.26 The response to cholestyramine in this study was greater than some other studies would predict.22'8 However, patients chosen for study were recruited on the basis that they were able to tolerate a full or near full dose of the resin.
BMJ VOLUME 304 23 MAY 1992 Nevertheless, cholestyramine was highly effective in lowering low density lipoprotein cholesterol concentrations in this study in resin tolerant patients. No consistent changes in values ofhigh density lipoprotein cholesterol were observed with either pravastatin or cholestyramine. Plasma triglyceride concentrations showed the expected small increase with cholestyramine. 28 Pravastatin was generally well tolerated and side effects were few. The principal problems with other available reductase inhibitors have been rises in hepatocellular enzyme activities (greater than threefold increase) in 1I0-IF5% of patients and a rare myositis-like syndrome with raised plasma activities of creatine kinase (>10-fold increase) in 0 5% of subjects.29 These effects are generally reversible on cessation oftreatment although rhabdomyolysis has rarely been described in patients receiving lovastatin combined with cyclosporin, nicotinic acid, and gemfibrozil.2333 In this study no patient was withdrawn because of a myositislike syndrome or excessive rises in creatine kinase activities. No patients were withdrawn because of disturbances in hepatic enzymes.
Careful ophthalmological examination revealed no changes in ophthalmic status in any patient on either treatment. This is of importance as the compound triparanol, which was in trial in the 1960s as an inhibitor of cholesterol synthesis, led to cataract formation. However, this compound inhibits cholesterol synthesis at a late stage in the synthetic pathway, leading to a build up of toxic intermediates.34 Cataract development has not been observed in animals given long term high dose pravastatin. Furthermore, -the other available reductase inhibitors which can produce cataract formation in some high dose toxicology studies in animals have not resulted in ophthalmological problems in humans. 9 3536 CONCLUSION In conclusion, pravastatin seems to be an effective, well tolerated compound for treating severe hypercholesterolaemia. Cholestyramine when tolerated at high dose is also highly effective. Evidence from other studies indicates that the combination of pravastatin with cholestyramine has a greater effect in reducing low density lipoprotein cholesterol values than either compound used alone.'4 Moreover, with regard to compliance, particularly when the drug needs to be taken with cholestyramine, it is now recognised that once daily dosing in the evening is as effective as twice daily dosing at the same total daily dosage. 14 
